Serum sickness-like reaction associated with efalizumab

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 383-386

  Ashraf Benson, Sadia ^a   Wall, Geoffrey C ^a,b,c   Veach, Lisa A ^b,d  

^a IOWA METHODIST MEDICAL CENTER   (United States)

^b IMMC ^*  (United States)

^c DRAKE UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Efalizumab; Serum sickness

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CORTICOSTEROID; EFALIZUMAB; METHYLPREDNISOLONE; VANCOMYCIN;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; HOSPITALIZATION; HUMAN; JOINT SWELLING; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RASH; SERUM SICKNESS LIKE REACTION; SIDE EFFECT; SINGAPORE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; SERUM SICKNESS;

EID: 60349084508     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L495     Document Type: Article

References (15)

1. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14.
2. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006;54(4 suppl 1):S182-8.
3. Maartje A, Berends M, Rieke J, Driessen B, Annechien M, Langewouters G. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatol Treat 2007;18:76-83.
4. Product information. Raptiva (efalizumab). www.gene.com/gene/products/ information/immunological/raptiva/insert.jsp (accessed 2008 Sept 5).
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990;132:336-42.
7. Evans R, Kim K, Mahr TA. Current concepts in allergy: drug reactions. Curr Problems Pediatr 1991;21:185-92.
8. Ditto AM. Introduction, epidemiology, classification of adverse reactions, immunochemical basis, risk factors, evaluation of patients with suspected drug allergy, patient management considerations. In: Grammer LC, Greenberger PA, eds. Patterson's allergic diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:307-8.
9. Lawley T, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 1984;311:1407-13.
10. Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin North Am 2007;25:245-53.
11. Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23:451-63.
12. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007;34:430-3.
13. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006;30:41-4.
14. Krishnan RS, Hsu S. Serum sickness due to infliximab in a patient with psoriasis. J Drugs Dermatol 2004;3:305-8.
15. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Exp Opin Drug Saf 2006;5:197-209.